PMC

Challenges and limitations in completed and currently ongoing immuno-oncology clinical trials. Abbreviations: BM, bone marrow transplant; PS, performance status.

FDA approval timeline of immune checkpoint inhibitors in advanced/metastatic malignancies (https://www.fda.gov/drugs, retrieved May 31, 2017). Abbreviations: A, any line; cHL, classical Hodgkin lymphoma; dMMR, mismatch repair deficient; F, first line; HSCT, hematopoietic stem cell transplant; L, fourth or beyond line; MSI-H, microsatellite instability-high; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma; S, second or beyond line; SCCHN, squamous cell carcinoma of the head and neck; WT, wild-type.